About Us
Finding Inspiration in every health Obstacle
NostraBiome was founded by Calin Popescu, a serial entrepreneur and inventor who endured over a decade of unresponsive IBD. Frustrated by the limited treatment options, Mr. Popescu leveraged his technological expertise to create a personalized approach to understanding and treating the disease. Today, some of the most experienced doctors, scientists, and researchers have joined our team, embarking on a new chapter for immune disease therapies
Our leadership team
Our Story
After extensive testing and analysis, Mr. Popescu discovered correlations and patterns in the disease that allowed him to attack specific elements and gradually improve his symptoms. He realized that IBD requires a personalized approach, tailored to the unique factors that influence the disease in each individual.
We believe that precision and personalized medicine are the key to solving the complex puzzle of our immune system. Using groundbreaking innovations in computer simulations and artificial intelligence, we aim to hack and break the inflammatory code of each individual and recommend chronological steps to reverse the symptoms of the disease.
Our mission is to offer hope and improve the quality of life for over 6 million people worldwide who suffer from IBD, as well as the millions more affected by autoimmune, chronic conditions, and oncology-related diseases. While we recognize that not all individuals may benefit from our approach, we remain committed to leveraging cutting-edge technology and medical expertise to make a meaningful difference in the lives of those who can
Our Thesis
Our thesis posits that by detecting unique and dynamic microbial signatures in the intestinal microbiome of each patient, we can unlock valuable insights into health and disease. The intestinal microbiome, the largest organism and ecosystem within our bodies, exerts a profound yet unquantified influence on the entire immune system. By identifying the specific ways in which each patient's microbiome overloads their immune response, we can generate targeted recommendations to alter and modify these signatures, disrupting the vicious cycle that affects health.
​
This personalized approach significantly enhances the efficacy of therapies for conditions such as inflammatory bowel disease (IBD) and various cancers that utilize immunotherapy. We are introducing a hyper-personalized step in the treatment journey for these diseases, incorporating a fine-tuning element that dramatically increases treatment efficiency. By aligning therapies with the unique microbial landscapes of each individual, we aim to optimize patient outcomes and improve the overall quality of life for those affected.
